Department of Psychiatry, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
Department of Psychiatry, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; McLean Hospital, Belmont, MA.
J Acad Consult Liaison Psychiatry. 2023 Jan-Feb;64(1):35-44. doi: 10.1016/j.jaclp.2022.07.010. Epub 2022 Aug 8.
Delirium is common in the setting of infection with severe acute respiratory syndrome coronavirus 2. Anecdotal evidence and case reports suggest that patients with delirium in the setting of Coronavirus 2019 (COVID-19) may exhibit specific features, including increased tone, abulia, and alogia.
To determine whether differences exist in sociodemographic and medical characteristics, physical examination findings, and medication use in delirious patients with and without COVID-19 infection referred for psychiatric consultation.
We undertook an exploratory, retrospective chart review of 486 patients seen by the psychiatry consultation service at a tertiary care hospital from March 10 to May 15, 2020. Delirious patients were diagnosed via clinical examination by a psychiatric consultant, and these patients were stratified by COVID-19 infection status. The strata were described and compared using bivariate analyses across sociodemographic, historical, objective, and treatment-related variables.
A total of 109 patients were diagnosed with delirium during the study period. Thirty-six were COVID-19+. Median age was 63 years and did not differ between groups. COVID-19+ patients with delirium were more likely to present from nursing facilities (39% vs 11%; Fisher's exact test; P = 0.001) and have a history of schizophrenia (11% vs 0%; Fisher's exact test; P = 0.011). Myoclonus (28% vs 4%; P = 0.002), hypertonia (36% vs 10%; P = 0.003), withdrawal (36% vs 15%; P = 0.011), akinesia (19% vs 6%; P = 0.034), abulia (19% vs 3%; P = 0.004), and alogia (25% vs 8%; P = 0.012) were more common in COVID-19+ patients. COVID-19+ delirious patients were significantly more likely to have received ketamine (28% vs 7%; P = 0.006), alpha-adrenergic agents besides dexmedetomidine (36% vs 14%; P = 0.014), and enteral antipsychotics (92% vs 66%; P = 0.007) at some point.
Patients with COVID-19 delirium referred for psychiatric consultation are more likely to reside in nursing facilities and have a history of schizophrenia than delirious patients without COVID-19. Patients with delirium in the setting of COVID-19 may exhibit features consistent with akinetic mutism. Psychiatrists must assess for such features, as they may influence management choices and the risk of side effects with agents commonly used in the setting of delirium.
在严重急性呼吸系统综合征冠状病毒 2 感染的情况下,谵妄很常见。传闻证据和病例报告表明,在 2019 年冠状病毒病(COVID-19)环境中出现谵妄的患者可能表现出特定的特征,包括肌张力增高、无动力和少语。
确定在因感染 COVID-19 而转介到精神病学咨询的谵妄患者和未感染 COVID-19 的谵妄患者中,在社会人口学和医学特征、体格检查结果和药物使用方面是否存在差异。
我们对 2020 年 3 月 10 日至 5 月 15 日在一家三级护理医院接受精神病学咨询服务的 486 名患者进行了探索性、回顾性图表审查。通过精神病学顾问的临床检查诊断出谵妄患者,根据 COVID-19 感染状况对这些患者进行分层。使用双变量分析在社会人口学、历史、客观和治疗相关变量方面对各层进行描述和比较。
在研究期间,共有 109 名患者被诊断为谵妄。36 例为 COVID-19+。中位年龄为 63 岁,两组之间没有差异。患有谵妄的 COVID-19+患者更有可能从护理机构就诊(39% vs 11%;Fisher 确切检验;P=0.001),并有精神分裂症病史(11% vs 0%;Fisher 确切检验;P=0.011)。肌阵挛(28% vs 4%;P=0.002)、肌张力增高(36% vs 10%;P=0.003)、戒断(36% vs 15%;P=0.011)、运动不能(19% vs 6%;P=0.034)、无动力(19% vs 3%;P=0.004)和少语(25% vs 8%;P=0.012)在 COVID-19+患者中更为常见。COVID-19+谵妄患者更有可能接受过氯胺酮(28% vs 7%;P=0.006)、除右美托咪定以外的α-肾上腺素能药物(36% vs 14%;P=0.014)和肠内抗精神病药(92% vs 66%;P=0.007)。
因 COVID-19 而转介到精神病学咨询的 COVID-19 谵妄患者比未感染 COVID-19 的谵妄患者更有可能居住在护理机构并有精神分裂症病史。在 COVID-19 环境中出现谵妄的患者可能表现出类似于无动性缄默症的特征。精神科医生必须评估这些特征,因为它们可能会影响管理决策和常用药物的副作用风险。